• 목록
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

The decision to stop or continue ADHD medication during pregnancy and breastfeeding is a challenge for women suffering from the condition. There is a lack of information about how long-term exposure to these medications could affect the fetus.

A recent study published in Molecular Psychiatry shows that children exposed to Adhd Medication List Uk medication during utero do not develop neurological developmental conditions like hearing loss or impaired vision, febrile seizures, or IQ impairment. The authors acknowledge that more high-quality research is needed.

Risk/Benefit Analysis

Pregnant women who take ADHD medications need to balance the benefits of taking them against the potential risks to the foetus. Physicians do not have the data needed to provide clear recommendations however they can provide information regarding the risks and benefits to aid pregnant women in making informed choices.

A study published in Molecular Psychiatry found that women who used ADHD medications during early pregnancy did not face a significantly higher risk of fetal cardiac malformations or major structural birth defects. Researchers conducted a massive population-based study of case control to compare the incidence of major structural defects in infants who were born to mothers who were taking stimulants during pregnancy. Clinical geneticists and pediatric cardiologists looked over the cases to ensure accurate case classification and to limit the possibility of bias.

However, the study had its limitations. Researchers were unable in the beginning, to separate the effects of the medication from the disorder. This limitation makes it difficult for researchers to determine if the small associations observed among the groups exposed were due to the use of medication or if they were affected by co-morbidities. In addition the study did not look at the long-term outcomes of offspring.

The study did show that infants whose mothers took ADHD medication during pregnancy were at a slightly higher risk of being admitted to the neonatal intensive care unit (NICU) than infants whose mothers had not taken any medication or had stopped their medications before or during pregnancy. This was due to central nervous system disorders. The increased risk of admission was not influenced by the stimulant medications used during pregnancy.

Women who were taking stimulant ADHD medications during pregnancy also had a higher chance of having to have an emergency caesarean section or having a baby that scored low on the Apgar scale (less than 7). These increases did not appear to be affected by the type of medication that was used during pregnancy.

Researchers suggest that the small risks associated with the use adhd medication pregnancy medications in early pregnancies could be offset by the greater benefits to both mother and baby of continuing treatment for the woman's disorder. Physicians should discuss this with their patients and, where possible, help them develop strategies to improve their coping abilities that may minimize the negative impact of her condition on her daily functioning and relationships.

Medication Interactions

As more women than ever before are being diagnosed with ADHD and treated with medication, the question of whether or not to discontinue treatment during pregnancy is one that more and more physicians confront. These decisions are often taken without clear and authoritative evidence. Instead, doctors must take into account their own experience and experience, as well as the experiences of other doctors and the research that has been conducted on the subject.

In particular, the issue of potential risks for the baby can be a challenge. A lot of studies on this issue are based on observations rather than controlled research and their findings are often contradictory. In addition, most studies limit their analysis to live births, which can underestimate severe teratogenic effects that result in abortion or termination of the pregnancy. The study discussed in the journal club addresses these limitations by analyzing the data from deceased and live births.

The conclusion is that while some studies have found that there is a positive correlation between ADHD medications and the possibility of certain birth defects, others have found no connection, and most studies demonstrate a neutral or slightly negative impact. In the end, a careful risk/benefit assessment must be conducted in every instance.

For a lot of women with ADHD who suffer from ADHD, the decision to stop medication can be difficult, if not impossible. In a recent article in the Archives of Women's Mental Health psychologist Jennifer Russell notes that stopping ADHD medication during pregnancy can increase depression, feelings of isolation and family conflict for these patients. Additionally, the loss of medication may affect the ability to complete work-related tasks and safely drive which are essential aspects of daily life for many people suffering from ADHD.

She recommends women who are unsure about whether to keep or discontinue medication due to their pregnancy consider informing family members, friends and colleagues about the condition, its effects on daily life, and the advantages of continuing the current treatment regimen. It will also help a woman feel confident about her decision. It is important to note that certain medications can pass through the placenta, therefore, if a patient decides to discontinue her ADHD medication during pregnancy and breastfeeding, she must be aware that the effects of the drug can be transferred to the infant.

Risk of Birth Defects

As the use of ADHD drugs to treat symptoms of attention deficit hyperactivity disorder (ADHD) grows, so do concerns about the effects that the drugs might have on the fetuses. A study that was published in the journal Molecular Psychiatry adds to the body of knowledge on this subject. Utilizing two huge data sets researchers were able examine more than 4.3 million pregnancies and see whether stimulant medications increased the risk of birth defects. Researchers discovered that although the overall risk is low, the first trimester ADHD exposure to medication was associated with slightly higher risk of specific heart defects like ventriculoseptal defects.

The researchers of the study found no link between the use of early medications and other congenital anomalies, like facial clefting, or club foot. The results are in agreement with previous studies that have shown the existence of a slight, but significant increase in cardiac malformations for women who started taking ADHD medication prior to the birth of their child. This risk increased during the latter half of pregnancy, when a lot of women decided to stop taking their medication.

Women who took ADHD medications in the first trimester of their pregnancies were also more likely to have a caesarean section, a low Apgar score following delivery, and a baby that required breathing assistance at birth. The authors of the study were not able to remove bias in selection since they limited the study to women with no other medical conditions that could have contributed to the findings.

Researchers hope their research will provide doctors with information when they see pregnant women. They recommend that, while discussing the risks and benefits is crucial, the decision to stop or maintain medication should be based on the woman's requirements and the severity of her ADHD symptoms.

The authors also advise that, while stopping the medication is an alternative, it is not an option to consider due to the high rate of depression and other mental health problems among women who are pregnant or postpartum. Research has also shown that women who stop taking their medication will have a harder time adjusting to a life without them after the baby is born.

Nursing

The responsibilities of a new mom can be overwhelming. Women with ADHD who have to deal with their symptoms while attending doctor appointments, making preparations for the arrival of their child and adapting to new routines in the home can experience severe challenges. As such, many women decide to continue taking their ADHD medication throughout the pregnancy.

The majority of stimulant drugs are absorbed through breast milk in low quantities, so the risk to the nursing infant is very low. The amount of exposure to medications will differ based on dosage the medication is administered, its frequency and the time of day. In addition, various drugs enter the infant's system via the gastrointestinal tract or breast milk. The effect on the health of a newborn is not fully known.

Some doctors may stop taking stimulant medications during a woman's pregnancy due to the lack of research. It's a difficult choice for the mother, who must weigh the advantages of her medication against the risks to the foetus. In the meantime, until more information is available, GPs can inquire about pregnant patients if they have any background of ADHD or if they are planning to take medication during the perinatal phase.

Many studies have shown that women can continue taking their adhd medication and pregnancy medication in a safe manner during pregnancy and while breast-feeding. As a result, more and more patients are choosing to do so and in consultation with their physician, they have discovered that the benefits of continuing their current medication far exceed any risk.

Women with ADHD who are planning to breastfeed should seek advice from an expert psychiatrist prior to becoming pregnant. They should discuss their medication with their prescriber, and the pros and cons for continuing treatment. This includes non prescription adhd medication uk-pharmacological methods. Psychoeducation should also be offered to help pregnant people with ADHD understand their symptoms and the underlying disorder and learn about treatments and to reinforce existing coping strategies. This should be a multidisciplinary approach together with obstetricians, GPs and psychiatrists. Pregnancy counseling should include discussion of a treatment plan for the mother and the child, monitoring of indicators of deterioration, and, if needed adjustments to the medication regimen.